[go: up one dir, main page]

NO20045534L - Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon - Google Patents

Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon

Info

Publication number
NO20045534L
NO20045534L NO20045534A NO20045534A NO20045534L NO 20045534 L NO20045534 L NO 20045534L NO 20045534 A NO20045534 A NO 20045534A NO 20045534 A NO20045534 A NO 20045534A NO 20045534 L NO20045534 L NO 20045534L
Authority
NO
Norway
Prior art keywords
female sexual
sexual dysfunction
methods
compositions
relief
Prior art date
Application number
NO20045534A
Other languages
English (en)
Inventor
James L Yeager
Nadir Bueyuektimkin
Mingqi Lu
Y Joseph Mo
Servet Bueyuektimkin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of NO20045534L publication Critical patent/NO20045534L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen tilveiebringer preparater og metoder som er egnet for å lindre kvinnelig seksuell feilfunksjon, og spesielt en forstyrrelse i kvinnelig seksuell tenning. l én utførelsesform tilveiebringer oppfinnelsen et halvfast preparat som er egnet for topisk påføring, omfattende: en effektiv mengde av et vasoaktivt prostaglandin, et inntrengningsforbedringsmiddel, et polymerfortykningsmiddel, en lipofil bestanddel og et surt buffersystem.
NO20045534A 2002-07-02 2004-12-17 Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon NO20045534L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/188,554 US6825234B2 (en) 1998-12-10 2002-07-02 Compositions and methods for amelioration of human female sexual dysfunction
PCT/US2003/020779 WO2004004689A1 (en) 2002-07-02 2003-07-02 Compositions and methods for amelioration of human female sexual dysfunction

Publications (1)

Publication Number Publication Date
NO20045534L true NO20045534L (no) 2005-03-01

Family

ID=30114011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045534A NO20045534L (no) 2002-07-02 2004-12-17 Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon

Country Status (10)

Country Link
US (1) US6825234B2 (no)
EP (1) EP1517672A1 (no)
JP (1) JP2005535658A (no)
CN (1) CN1665485A (no)
AU (1) AU2003248785A1 (no)
CA (1) CA2489563A1 (no)
NO (1) NO20045534L (no)
NZ (1) NZ537276A (no)
WO (1) WO2004004689A1 (no)
ZA (1) ZA200410009B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040241243A1 (en) * 2003-03-21 2004-12-02 Nexmed (Holdings) Inc. Angiogenesis promotion by prostaglandin compositions and methods
MXPA05010552A (es) * 2003-04-02 2005-11-23 Nexmed Holdings Inc Composiciones de prostaglandina y su uso para el tratamiento de vasoespasmos.
US20050239742A1 (en) * 2004-04-08 2005-10-27 Vivus, Inc. Carrageenan-based formulations and associated methods of use
KR100558012B1 (ko) * 2004-07-16 2006-03-06 삼성전자주식회사 반도체 메모리 소자
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
BR112013025744A2 (pt) 2011-04-07 2016-08-16 Nexmed Holdings Inc composicões para tratamento da doença de raynaud
CA2894696A1 (en) 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3852465A (en) 1972-09-21 1974-12-03 Upjohn Co Abortion by myometrial administration of prostaglandins
US4005221A (en) 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4217360A (en) 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4043339A (en) 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
JPS52156913A (en) 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
AU519132B2 (en) 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
JPS5573676A (en) 1978-11-30 1980-06-03 Ono Pharmaceut Co Ltd Simulated compound of prostaglandin i2 and its preparation
JPS5589297A (en) 1978-12-28 1980-07-05 Kureha Chem Ind Co Ltd Prostaglandin derivative, its preparation and its drug
SE431821B (sv) 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
USRE30439E (en) 1979-03-12 1980-11-25 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4317447A (en) 1979-07-19 1982-03-02 Ortho Pharmaceutical Corporation Drug delivery system
US4318908A (en) 1979-12-06 1982-03-09 Kureha Kagaku Kogyo Kabushiki Kaisha Methylated prostaglandin derivatives
US4289785A (en) 1980-08-06 1981-09-15 The Upjohn Company Method and compositions involving prostaglandins
ZA831186B (en) 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4515810A (en) 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US4771004A (en) 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
EP0266968A3 (en) 1986-11-03 1988-08-24 Gérard G. Cohen Gelled ointment of vasodilating agent
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
JPS63135333A (ja) 1986-11-26 1988-06-07 Nitto Electric Ind Co Ltd プロスタグランジン類含有貼付剤
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
IT1221826B (it) 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
JP2910857B2 (ja) 1989-04-04 1999-06-23 ニチバン株式会社 プロスタグランジンｅ１経皮吸収製剤
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
EP0526566B1 (en) 1990-04-25 1998-11-25 Vivus, Inc. Treatment of erectile dysfunction
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5981593A (en) 1991-07-03 1999-11-09 Scott; Nathan Earl Prostaglandin E2 treatment of impotence
WO1993000894A1 (en) 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US6291528B1 (en) 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
NZ244862A (en) 1991-10-23 1995-07-26 Block Drug Co Use of vitamin e in topical pharmaceuticals to enhance penetration of the active agent
AU664719B2 (en) 1991-11-08 1995-11-30 Green Cross Corporation, The Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
ATE187071T1 (de) 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
EP0814775A1 (en) 1995-03-14 1998-01-07 Vivus, Inc. Method and kit for preventing erectile dysfunction
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
ES2191834T3 (es) * 1996-10-24 2003-09-16 Alza Corp Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US20020004529A1 (en) 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
CA2314369A1 (en) 1997-12-18 1999-06-24 Nathan Earl Scott Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6046240A (en) 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6403658B1 (en) 2000-09-21 2002-06-11 Shaina Toppo Genital vasodilator

Also Published As

Publication number Publication date
WO2004004689A1 (en) 2004-01-15
EP1517672A1 (en) 2005-03-30
CN1665485A (zh) 2005-09-07
ZA200410009B (en) 2006-06-28
US20030129241A1 (en) 2003-07-10
CA2489563A1 (en) 2004-01-15
NZ537276A (en) 2007-06-29
US6825234B2 (en) 2004-11-30
AU2003248785A1 (en) 2004-01-23
JP2005535658A (ja) 2005-11-24
WO2004004689A8 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20045534L (no) Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon
DK1137409T3 (da) Præparater og fremgangsmåde til lindring af human kvindelig seksuel dysfunktion
EP2513343A4 (en) METHODS AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
TW200505508A (en) Methods of administering a dermatological agent to a subject
WO2004089357A3 (en) Anti-fungal formulation of triterpene and essential oil
MX2010005210A (es) Formulacion de aceite de oliva para alivio del dolor.
EP2351561A3 (en) Novel methods and compositions for alleviating pain
MXPA06002726A (es) Metodo para identificar agonistas mejorados no sedantes de alfa-2.
BRPI0411826A (pt) métodos de prevenir e reduzir a gravidade de estados associados ao estresse
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
CA2420895A1 (en) Method for treating erectile dysfunction and increasing libido in men
ECSP088363A (es) Gel de testosterona y metodo de uso
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
WO2009015014A3 (en) Multi-step method of pain and/or inflammation treatment
WO2005023193A3 (en) Methods of treating endometriosis
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
AR047796A1 (es) Composiciones cosmeticas que exhiben propiedades humectantes duraderas
WO2003024436A3 (en) Method for treating skin disorders
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
DK2051710T3 (da) Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment
WO2003032985A3 (en) Concomitant oral and topical administration of anti - infective agents
DE60134002D1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels
WO2005074995A3 (en) Combined use of prame inhibitors and hdac inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application